Induction Chemotherapy Comparing Taxotere® Cisplatin and 5-Fluorouracil (TPF) With Standard Cisplatin and 5-Fluorouracil (PF) Followed by Chemoradiation in Locally Advanced Head and Neck Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Marshall Posner, MD
Dana-Farber Cancer Institute
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Sanofi-Aventis Administrative Office
Buenos Aires, Argentina
- Sanofi-Aventis Administrative Office
Laval, Canada
- Sanofi-Aventis Administrative Office
Paris, France
- Sanofi-Aventis Administrative Office
Porto Salvo, Portugal
- Sanofi-Aventis Administrative Office
Moscow, Russia
- Sanofi-Aventis Administrative Office
Bridgewater, New Jersey, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 1999
- Primary completion
- 28 Feb 2006
- Completion
- 28 Feb 2006
- Last update posted
- 29 Apr 2009
- Registered enrollment
- 500
- Registry id
- NCT00273546
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.